$10.97
1.95% yesterday
Nasdaq, Aug 25, 10:00 pm CET
ISIN
US55083R1041
Symbol
LYEL

Lyell Immunopharma Inc Stock price

$10.97
-1.45 11.67% 1M
-2.18 16.59% 6M
-1.83 14.30% YTD
-20.83 65.50% 1Y
-141.63 92.81% 3Y
-326.83 96.75% 5Y
-326.83 96.75% 10Y
-326.83 96.75% 20Y
Nasdaq, Closing price Mon, Aug 25 2025
+0.21 1.95%
ISIN
US55083R1041
Symbol
LYEL
Industry

Key metrics

Basic
Market capitalization
$206.7m
Enterprise Value
$-70.1m
Net debt
positive
Cash
$276.8m
Shares outstanding
14.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
3,445.2 | 18,993.1
EV/Sales
negative | negative
EV/FCF
0.3
P/B
0.7
Financial Health
Equity Ratio
78.0%
Return on Equity
-89.6%
ROCE
-61.7%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$60.0k | $10.9k
EBITDA
$-198.9m | $-217.7m
EBIT
$-215.2m | $-239.6m
Net Income
$-331.4m | $-246.0m
Free Cash Flow
$-203.3m
Growth (TTM | estimate)
Revenue
0.0% | -81.8%
EBITDA
3.2% | -8.5%
EBIT
4.6% | -8.8%
Net Income
-57.6% | 28.3%
Free Cash Flow
-27.9%
Margin (TTM | estimate)
Gross
-
EBITDA
-331,485.0% | -2,000,393.6%
EBIT
-358,621.7%
Net
-552,328.3% | -2,259,941.9%
Free Cash Flow
-338,905.0%
More
EPS
$-22.4
FCF per Share
$-13.7
Short interest
1.2%
Employees
300
Rev per Employee
$0.0
Show more

Is Lyell Immunopharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,019 stocks worldwide.

Lyell Immunopharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Lyell Immunopharma Inc forecast:

3x Hold
43%
4x Sell
57%

Analyst Opinions

7 Analysts have issued a Lyell Immunopharma Inc forecast:

Hold
43%
Sell
57%

Financial data from Lyell Immunopharma Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
0.06 0.06
0% 0%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 50 50
8% 8%
83,533%
- Research and Development Expense 168 168
5% 5%
280,733%
-199 -199
3% 3%
-331,483%
- Depreciation and Amortization 16 16
19% 19%
27,133%
EBIT (Operating Income) EBIT -215 -215
5% 5%
-358,622%
Net Profit -331 -331
58% 58%
-552,333%

In millions USD.

Don't miss a Thing! We will send you all news about Lyell Immunopharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Lyell Immunopharma Inc Stock News

Neutral
GlobeNewsWire
13 days ago
SOUTH SAN FRANCISCO, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing next-generation CAR T-cell therapies for patients with cancer, today reported financial results and business highlights for the second quarter ended June 30, 2025. Lyell's lead clinical program, LYL314, is a next-generation autologous dual-targeting CD1...
Neutral
GlobeNewsWire
about one month ago
SOUTH SAN FRANCISCO, Calif., July 25, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing next-generation CAR T-cell therapies for patients with cancer, today announced that it has entered into a securities purchase agreement for a private placement with certain institutional and other accredited investors, for gross proceeds of up to approximate...
Positive
Seeking Alpha
about one month ago
Lyell Immunopharma's LYL314 CAR-T therapy shows high, durable response rates in 3rd-line + Large B-Cell Lymphoma patients. The company has initiated a phase 3 trial for LYL314 in 3rd-line + LBCL following positive FDA feedback after the end-of-phase 1 meeting. A key upcoming catalyst is the planned phase 3 trial in 2nd-line + LBCL patients, expected to begin in early 2026.
More Lyell Immunopharma Inc News

Company Profile

Lyell Immunopharma, Inc. operates as a holding company, which engages in the development of cell-based immunotherapies for human diseases. The company was founded by Richard D. Klausner, Stan Riddell, and Crystal Mackall in June 2018 and is headquartered in South San Francisco, CA.

Head office United States
CEO Lynn Seely
Employees 300
Founded 2018
Website lyell.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today